PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 3, 2026Nature Cardiovascular Research0 citations

A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy

View Full Paper
HBHarshvir S. BalAPAkhil PampanaANAmrita Nayak

Key Result

Individuals in the highest multiancestry polygenic risk score quintile had a 2.11-fold increased risk of HCM overall and a nearly 70-fold higher risk among SARC-HCM-P/LP carriers.

Key Points

  • To develop a multiancestry polygenic risk score for hypertrophic cardiomyopathy and assess its ability to improve disease risk prediction and outcome stratification across diverse ancestral groups.
  • Constructed a multiancestry polygenic risk score (PRS) using summary statistics from BioBank Japan, the Million Veteran Program, and a meta-analysis of seven European-ancestry cohorts.
  • Evaluated PRS association with disease diagnosis and adverse cardiovascular outcomes in a USA-based multiancestry validation cohort.
  • Individuals in the highest PRS quintile had a 2.11-fold increased risk of hypertrophic cardiomyopathy overall and a nearly 70-fold increased risk among sarcomere pathogenic/likely pathogenic variant carriers.
  • Higher PRS values were associated with adverse cardiovascular outcomes in patients with hypertrophic cardiomyopathy and demonstrated trends toward improved ancestry-specific prediction.

Study Design

Type

Observational

Multicenter

Yes

Structured PICO

Does a multiancestry polygenic risk score improve risk stratification for hypertrophic cardiomyopathy in a multiancestry population?

P
Population
USA-based multiancestry population, including individuals with hypertrophic cardiomyopathy (HCM) and SARC-HCM-P/LP carriers
E
Exposure
Multiancestry polygenic risk score (PRS) derived from BioBank Japan, Million Veteran Program and a meta-analysis of seven European-ancestry cohorts
C
Comparator
Lower PRS quintiles
O
Outcome
Risk of hypertrophic cardiomyopathy (HCM)hard clinical

A multiancestry polygenic risk score significantly improves risk stratification for hypertrophic cardiomyopathy, particularly among carriers of pathogenic sarcomere variants.

Main Result

Effect estimate: 2.11-fold increased risk

Abstract

Hypertrophic cardiomyopathy (HCM) has traditionally been considered a Mendelian disease driven by pathogenic or likely pathogenic variants in sarcomere-encoding genes (SARC-HCM-P/LP). However, these variants explain only one-third of cases, and variable penetrance suggests additional polygenic contributions. Existing HCM polygenic risk scores (PRSs), largely derived from European-ancestry cohorts, have limited generalizability. Here we develop a multiancestry PRS using summary statistics from the BioBank Japan, Million Veteran Program and a meta-analysis of seven European-ancestry cohorts and evaluate its association with HCM in a USA-based multiancestry population. Individuals with the highest PRS quintile had a 2.11-fold increased risk of HCM in the overall population and nearly 70-fold higher risk among SARC-HCM-P/LP carriers. The PRS improved risk stratification and showed trends toward improved ancestry-specific prediction. Among individuals with HCM, a higher PRS was also associated with adverse cardiovascular outcomes. These findings support the integration of multiancestry PRSs into HCM risk assessment and prognostication.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bal et al. (2026) conducted an observational in Hypertrophic cardiomyopathy (HCM). Multiancestry polygenic risk score (PRS) vs. Lower PRS quintiles was evaluated on Hypertrophic cardiomyopathy (HCM) (2.11-fold increased risk). Individuals in the highest multiancestry polygenic risk score quintile had a 2.11-fold increased risk of HCM overall and a nearly 70-fold higher risk among SARC-HCM-P/LP carriers.

synapsesocial.com/papers/6a9967c6636c6408cfa7f8eahttps://doi.org/10.1038/s44161-026-00866-8
Ask AI
Helpful
Bookmark
Share
View Full Paper